Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is a clinical-stage immunotherapy company founded in 2015. Specializing in developing T cell engagers, Harpoon harnesses the body’s immune system to combat cancer and other serious diseases. Co-founded by Patrick Bauerle and Luke Evnin, the company leverages groundbreaking T cell recruiting antibodies to develop next-generation therapies. Harpoon's innovative platforms include the Tri-specific T cell Activating Construct (TriTAC®), ProTriTAC™, and TriTAC-XR. The TriTAC® platform aims to direct a patient's own immune cells to target and destroy tumor cells, primarily focusing on solid tumors and hematologic malignancies.
One of Harpoon's leading projects is HPN328, targeting delta-like ligand 3 (DLL3). Currently in a Phase 1/2 clinical trial, HPN328 shows promise in treating small cell lung cancer (SCLC) and other neuroendocrine tumors. Interim results indicate a 35% confirmed response rate in all tumor types studied, with higher efficacy observed in non-SCLC neuroendocrine tumors.
Harpoon's innovative approach extends to their proprietary ProTriTAC™ platform, which remains inactive until reaching the tumor, ensuring higher precision and reduced side effects. Additionally, the TriTAC-XR platform is designed to mitigate cytokine release syndrome, a common challenge in T cell therapies.
Financially, Harpoon has secured robust funding through recent PIPE financings, ensuring a solid runway into 2026. Strategic partnerships with leading oncology research centers and a strong focus on regulatory milestones underscore Harpoon's commitment to advancing cancer treatment. For more information, visit www.harpoontx.com.
- HPN328 received Orphan Drug Designation from the FDA in March 2022.
- The company is actively presenting data at major oncology conferences such as ESMO and ASCO-GU.
- Harpoon plans to meet with regulators in early 2024 to discuss further development plans for HPN328.
Harpoon Therapeutics (NASDAQ: HARP) announced three poster presentations at the AACR Annual Meeting, showcasing advances in T cell engagers for cancer treatment. The posters include findings on FLT3-targeting TriTACs for acute myeloid leukemia, the ProTriTAC™ platform, and the combinatorial effects of TriTACs with checkpoint inhibitors. Promising data indicate these approaches may enhance tumor specificity and efficacy. The company is advancing its ProTriTAC™ program (HPN601) and emphasizes the importance of further investigations for improved patient outcomes.
Harpoon Therapeutics (NASDAQ: HARP) has appointed Dr. Alan Colowick to its Board of Directors, enhancing its leadership team as the company navigates pivotal clinical developments. Dr. Colowick, a seasoned biotech expert, previously held executive roles at notable companies, including Celgene and Gloucester Pharmaceuticals. His extensive experience in oncology and clinical-stage companies is expected to provide valuable insights during this growth phase. Harpoon focuses on innovative T cell engagers to treat various cancers, currently advancing multiple candidates in clinical trials.
Harpoon Therapeutics (NASDAQ: HARP) announced the publication of abstracts for three poster presentations at the AACR Annual Meeting scheduled for April 10-15, 2021. The presentations will showcase advancements in their T cell engager platform targeting various cancers, including acute myeloid leukemia and solid tumors. Notable abstracts include research on FLT3-targeting TriTACs and ProTriTAC as a modular drug platform. The full abstracts will be accessible on Harpoon's website, promising insights into innovative cancer therapies.
Harpoon Therapeutics reported a significant pipeline update on March 10, 2021, highlighting advancements in its four TriTAC clinical trials. The company confirmed a partial response for HPN424 in metastatic castration-resistant prostate cancer. Financially, Harpoon ended Q4 2020 with $150 million in cash and raised $108.1 million through a public offering. Revenue surged to $7.5 million in Q4, up from $2.2 million year-over-year. Operating expenses also increased, with a projected cash burn of $85 to $95 million for 2021.
Harpoon Therapeutics (NASDAQ: HARP) announced that Jerry McMahon, Ph.D., President and CEO, will participate in a panel discussion titled “Pushing the Envelope on Bispecific Antibodies” at the 33rd Annual Roth Conference on March 16, 2021, at 3 p.m. ET. A live audio webcast will be available in the Investors section of Harpoon Therapeutics’ website, with an archived replay following the event. The company is developing T cell engagers for treating cancer using its proprietary TriTAC platform, with several candidates in clinical trials.
Harpoon Therapeutics (NASDAQ: HARP), a clinical-stage immunotherapy company, will report its fourth quarter and full year 2020 financial results on March 10, 2021. This will be accompanied by a corporate update. The management will host a webcast and conference call at 4:30 p.m. ET/1:30 p.m. PT. Investors can access the call by dialing 866-951-6894 domestically or 409-216-0624 internationally. Harpoon is developing a novel class of T cell engagers for cancer treatment, with various products in clinical trials.
Harpoon Therapeutics (NASDAQ: HARP) announced that Dr. Gerald McMahon, CEO, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 4:20 p.m. ET. The event will be accessible via live audio webcast through the Investors section of Harpoon's website. Harpoon Therapeutics is focused on developing innovative T cell engagers to harness the immune system for cancer treatment, utilizing their TriTAC platform and currently advancing multiple clinical trials targeting various cancers.
Harpoon Therapeutics (NASDAQ: HARP) announced that the FDA granted Orphan Drug Designation for its investigational drug HPN217, targeting multiple myeloma. This significant milestone recognizes HPN217's potential in addressing unmet medical needs. The drug is part of a Phase 1/2 clinical trial, with plans for interim data presentation later this year. Orphan status offers various incentives, including tax credits and seven-year marketing exclusivity upon approval. Harpoon's pipeline also includes other drug candidates targeting various malignancies.
Harpoon Therapeutics has successfully concluded its public offering, selling 6,764,704 shares of common stock. This includes 882,352 shares from the underwriters' full exercise of their option, yielding approximately $115.0 million in gross proceeds. The offering is based on a previously filed shelf registration statement with the SEC. SVB Leerink and Piper Sandler led the offering's management.
Harpoon Therapeutics (Nasdaq: HARP) has announced the pricing of a public offering of 5,882,352 shares at $17.00 each, aiming for approximately $100 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 882,352 shares. The funds will be allocated for the clinical development of various cancer treatments, including HPN424 for prostate cancer and HPN536 for ovarian cancer, as well as for general corporate purposes. The closing is anticipated on January 11, 2021, pending customary conditions.
FAQ
What is the market cap of Harpoon Therapeutics (HARP)?
What is Harpoon Therapeutics' primary focus?
What is the TriTAC® platform?
What are the recent clinical trial updates for HPN328?
What does the ProTriTAC™ platform do?
What is the significance of TriTAC-XR?
What financial steps has Harpoon taken recently?
What is HPN328 targeting?
When did HPN328 receive Orphan Drug Designation?
Where can I find more information about Harpoon Therapeutics?
What are Harpoon’s plans for HPN328 in 2024?
